APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney (Renal) Fibrosis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Kidney (Renal) Fibrosis Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchKidney (Renal) Fibrosis Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney (Renal) Fibrosis Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Kidney (Renal) Fibrosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney (Renal) Fibrosis Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney (Renal) Fibrosis Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney (Renal) Fibrosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Kidney (Renal) Fibrosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney (Renal) Fibrosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney (Renal) Fibrosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Kidney (Renal) Fibrosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Kidney (Renal) Fibrosis market include Merck, Roche, Pfizer, ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, InterMune, Genzyme Corporation, Galectin Therapeutics and BioLine Rx Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Kidney (Renal) Fibrosis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney (Renal) Fibrosis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney (Renal) Fibrosis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Kidney (Renal) Fibrosis market.

Kidney (Renal) Fibrosis Segment by Company

Merck

Roche

Pfizer

ProMetic Life-Sciences Inc.

La Jolla Pharmaceutical Company

InterMune

Genzyme Corporation

Galectin Therapeutics

BioLine Rx Ltd

Kidney (Renal) Fibrosis Segment by Type

Vasopeptidase Inhibitors

Angiotensin Converting enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Renin Inhibitors

Pirfenidone

Kidney (Renal) Fibrosis Segment by Application

Clinic

Hospital

Research Center

Kidney (Renal) Fibrosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Kidney (Renal) Fibrosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Kidney (Renal) Fibrosis key companies, revenue, market share, and recent developments.

3. To split the Kidney (Renal) Fibrosis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Kidney (Renal) Fibrosis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Kidney (Renal) Fibrosis significant trends, drivers, influence factors in global and regions.

6. To analyze Kidney (Renal) Fibrosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney (Renal) Fibrosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney (Renal) Fibrosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney (Renal) Fibrosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney (Renal) Fibrosis industry.

Chapter 3: Detailed analysis of Kidney (Renal) Fibrosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Kidney (Renal) Fibrosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Kidney (Renal) Fibrosis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Kidney (Renal) Fibrosis Industry Trends Table 2. Kidney (Renal) Fibrosis Industry Drivers Table 3. Kidney (Renal) Fibrosis Industry Opportunities and Challenges Table 4. Kidney (Renal) Fibrosis Industry Restraints Table 5. Global Kidney (Renal) Fibrosis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Kidney (Renal) Fibrosis Revenue Share by Company (2021-2026) Table 7. Global Kidney (Renal) Fibrosis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Kidney (Renal) Fibrosis Key Company Manufacturing Base & Headquarters Table 9. Global Kidney (Renal) Fibrosis Company, Product Type & Application Table 10. Global Kidney (Renal) Fibrosis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Kidney (Renal) Fibrosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vasopeptidase Inhibitors Table 15. Significant Companies of Angiotensin Converting enzyme (ACE) Inhibitors Table 16. Significant Companies of Angiotensin II Receptor Blockers (ARBs) Table 17. Significant Companies of Renin Inhibitors Table 18. Significant Companies of Pirfenidone Table 19. Global Kidney (Renal) Fibrosis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Kidney (Renal) Fibrosis Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Kidney (Renal) Fibrosis Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Kidney (Renal) Fibrosis Sales Value Share by Type (2021-2026) Table 23. Global Kidney (Renal) Fibrosis Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Clinic Table 25. Significant Companies of Hospital Table 26. Significant Companies of Research Center Table 27. Global Kidney (Renal) Fibrosis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Kidney (Renal) Fibrosis Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Kidney (Renal) Fibrosis Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Kidney (Renal) Fibrosis Sales Value Share by Application (2021-2026) Table 31. Global Kidney (Renal) Fibrosis Sales Value Share by Application (2027-2032) Table 32. Global Kidney (Renal) Fibrosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Kidney (Renal) Fibrosis Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Kidney (Renal) Fibrosis Sales Value Share by Region (2021-2026) Table 35. Global Kidney (Renal) Fibrosis Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Kidney (Renal) Fibrosis Sales Value Share by Region (2027-2032) Table 37. Global Kidney (Renal) Fibrosis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Kidney (Renal) Fibrosis Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Kidney (Renal) Fibrosis Sales Value Market Share by Country (2021-2026) Table 40. Global Kidney (Renal) Fibrosis Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Kidney (Renal) Fibrosis Sales Value Market Share by Country (2027-2032) Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck Kidney (Renal) Fibrosis Product Portfolio Table 46. Merck Recent Development Table 47. Roche Company Information Table 48. Roche Business Overview Table 49. Roche Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Roche Kidney (Renal) Fibrosis Product Portfolio Table 51. Roche Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Pfizer Kidney (Renal) Fibrosis Product Portfolio Table 56. Pfizer Recent Development Table 57. ProMetic Life-Sciences Inc. Company Information Table 58. ProMetic Life-Sciences Inc. Business Overview Table 59. ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Product Portfolio Table 61. ProMetic Life-Sciences Inc. Recent Development Table 62. La Jolla Pharmaceutical Company Company Information Table 63. La Jolla Pharmaceutical Company Business Overview Table 64. La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Product Portfolio Table 66. La Jolla Pharmaceutical Company Recent Development Table 67. InterMune Company Information Table 68. InterMune Business Overview Table 69. InterMune Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. InterMune Kidney (Renal) Fibrosis Product Portfolio Table 71. InterMune Recent Development Table 72. Genzyme Corporation Company Information Table 73. Genzyme Corporation Business Overview Table 74. Genzyme Corporation Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Genzyme Corporation Kidney (Renal) Fibrosis Product Portfolio Table 76. Genzyme Corporation Recent Development Table 77. Galectin Therapeutics Company Information Table 78. Galectin Therapeutics Business Overview Table 79. Galectin Therapeutics Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Galectin Therapeutics Kidney (Renal) Fibrosis Product Portfolio Table 81. Galectin Therapeutics Recent Development Table 82. BioLine Rx Ltd Company Information Table 83. BioLine Rx Ltd Business Overview Table 84. BioLine Rx Ltd Kidney (Renal) Fibrosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. BioLine Rx Ltd Kidney (Renal) Fibrosis Product Portfolio Table 86. BioLine Rx Ltd Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Kidney (Renal) Fibrosis Product Image Figure 2. Global Kidney (Renal) Fibrosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney (Renal) Fibrosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Kidney (Renal) Fibrosis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vasopeptidase Inhibitors Image Figure 8. Angiotensin Converting enzyme (ACE) Inhibitors Image Figure 9. Angiotensin II Receptor Blockers (ARBs) Image Figure 10. Renin Inhibitors Image Figure 11. Pirfenidone Image Figure 12. Global Kidney (Renal) Fibrosis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Kidney (Renal) Fibrosis Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Kidney (Renal) Fibrosis Sales Value Share by Type (2021-2032) Figure 15. Clinic Image Figure 16. Hospital Image Figure 17. Research Center Image Figure 18. Global Kidney (Renal) Fibrosis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Kidney (Renal) Fibrosis Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Kidney (Renal) Fibrosis Sales Value Share by Application (2021-2032) Figure 21. Global Kidney (Renal) Fibrosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Kidney (Renal) Fibrosis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Kidney (Renal) Fibrosis Sales Value (2021-2032) & (US$ Million) Figure 24. North America Kidney (Renal) Fibrosis Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Kidney (Renal) Fibrosis Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Kidney (Renal) Fibrosis Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Kidney (Renal) Fibrosis Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Kidney (Renal) Fibrosis Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Kidney (Renal) Fibrosis Sales Value (2021-2032) & (US$ Million) Figure 30. South America Kidney (Renal) Fibrosis Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Kidney (Renal) Fibrosis Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Kidney (Renal) Fibrosis Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Vasopeptidase Inhibitors
  • Angiotensin Converting enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Renin Inhibitors
  • Pirfenidone
Applications
  • Clinic
  • Hospital
  • Research Center
Companies covered
  • Merck
  • Roche
  • Pfizer
  • ProMetic Life-Sciences Inc.
  • La Jolla Pharmaceutical Company
  • InterMune
  • Genzyme Corporation
  • Galectin Therapeutics
  • BioLine Rx Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Kidney (Renal) Fibrosis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Kidney (Renal) Fibrosis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Kidney (Renal) Fibrosis Market Dynamics
  1. 2.1 Kidney (Renal) Fibrosis Industry Trends
  2. 2.2 Kidney (Renal) Fibrosis Industry Drivers
  3. 2.3 Kidney (Renal) Fibrosis Industry Opportunities and Challenges
  4. 2.4 Kidney (Renal) Fibrosis Industry Restraints
3 Kidney (Renal) Fibrosis Market by Company
  1. 3.1 Global Kidney (Renal) Fibrosis Company Revenue Ranking in 2025
  2. 3.2 Global Kidney (Renal) Fibrosis Revenue by Company (2021-2026)
  3. 3.3 Global Kidney (Renal) Fibrosis Company Ranking (2024-2026)
  4. 3.4 Global Kidney (Renal) Fibrosis Company Manufacturing Base and Headquarters
  5. 3.5 Global Kidney (Renal) Fibrosis Company Product Type and Application
  6. 3.6 Global Kidney (Renal) Fibrosis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Kidney (Renal) Fibrosis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Kidney (Renal) Fibrosis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Kidney (Renal) Fibrosis Market by Type
  1. 4.1 Kidney (Renal) Fibrosis Type Introduction
  2. 4.1.1 Vasopeptidase Inhibitors
  3. 4.1.2 Angiotensin Converting enzyme (ACE) Inhibitors
  4. 4.1.3 Angiotensin II Receptor Blockers (ARBs)
  5. 4.1.4 Renin Inhibitors
  6. 4.1.5 Pirfenidone
  7. 4.2 Global Kidney (Renal) Fibrosis Sales Value by Type
  8. 4.2.1 Global Kidney (Renal) Fibrosis Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Kidney (Renal) Fibrosis Sales Value by Type (2021-2032)
  10. 4.2.3 Global Kidney (Renal) Fibrosis Sales Value Share by Type (2021-2032)
5 Kidney (Renal) Fibrosis Market by Application
  1. 5.1 Kidney (Renal) Fibrosis Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.2 Global Kidney (Renal) Fibrosis Sales Value by Application
  6. 5.2.1 Global Kidney (Renal) Fibrosis Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Kidney (Renal) Fibrosis Sales Value by Application (2021-2032)
  8. 5.2.3 Global Kidney (Renal) Fibrosis Sales Value Share by Application (2021-2032)
6 Kidney (Renal) Fibrosis Regional Value Analysis
  1. 6.1 Global Kidney (Renal) Fibrosis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney (Renal) Fibrosis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Kidney (Renal) Fibrosis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Kidney (Renal) Fibrosis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Kidney (Renal) Fibrosis Sales Value (2021-2032)
  7. 6.3.2 North America Kidney (Renal) Fibrosis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Kidney (Renal) Fibrosis Sales Value (2021-2032)
  10. 6.4.2 Europe Kidney (Renal) Fibrosis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Kidney (Renal) Fibrosis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Kidney (Renal) Fibrosis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Kidney (Renal) Fibrosis Sales Value (2021-2032)
  16. 6.6.2 South America Kidney (Renal) Fibrosis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Kidney (Renal) Fibrosis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Kidney (Renal) Fibrosis Sales Value Share by Country, 2025 VS 2032
7 Kidney (Renal) Fibrosis Country-level Value Analysis
  1. 7.1 Global Kidney (Renal) Fibrosis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Kidney (Renal) Fibrosis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Kidney (Renal) Fibrosis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Kidney (Renal) Fibrosis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Kidney (Renal) Fibrosis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Kidney (Renal) Fibrosis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Kidney (Renal) Fibrosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Kidney (Renal) Fibrosis Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Kidney (Renal) Fibrosis Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Kidney (Renal) Fibrosis Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 ProMetic Life-Sciences Inc.
  20. 8.4.1 ProMetic Life-Sciences Inc. Company Information
  21. 8.4.2 ProMetic Life-Sciences Inc. Business Overview
  22. 8.4.3 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Product Portfolio
  24. 8.4.5 ProMetic Life-Sciences Inc. Recent Developments
  25. 8.5 La Jolla Pharmaceutical Company
  26. 8.5.1 La Jolla Pharmaceutical Company Company Information
  27. 8.5.2 La Jolla Pharmaceutical Company Business Overview
  28. 8.5.3 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Product Portfolio
  30. 8.5.5 La Jolla Pharmaceutical Company Recent Developments
  31. 8.6 InterMune
  32. 8.6.1 InterMune Company Information
  33. 8.6.2 InterMune Business Overview
  34. 8.6.3 InterMune Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 InterMune Kidney (Renal) Fibrosis Product Portfolio
  36. 8.6.5 InterMune Recent Developments
  37. 8.7 Genzyme Corporation
  38. 8.7.1 Genzyme Corporation Company Information
  39. 8.7.2 Genzyme Corporation Business Overview
  40. 8.7.3 Genzyme Corporation Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Corporation Kidney (Renal) Fibrosis Product Portfolio
  42. 8.7.5 Genzyme Corporation Recent Developments
  43. 8.8 Galectin Therapeutics
  44. 8.8.1 Galectin Therapeutics Company Information
  45. 8.8.2 Galectin Therapeutics Business Overview
  46. 8.8.3 Galectin Therapeutics Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Galectin Therapeutics Kidney (Renal) Fibrosis Product Portfolio
  48. 8.8.5 Galectin Therapeutics Recent Developments
  49. 8.9 BioLine Rx Ltd
  50. 8.9.1 BioLine Rx Ltd Company Information
  51. 8.9.2 BioLine Rx Ltd Business Overview
  52. 8.9.3 BioLine Rx Ltd Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioLine Rx Ltd Kidney (Renal) Fibrosis Product Portfolio
  54. 8.9.5 BioLine Rx Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst